Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00754117 · ClinicalTrials.gov registry record
Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- 8
- Enrollment target
NCT00754117: Completed study, sponsored by Weill Medical College of Cornell University.
NCT00754117 is a clinical trial that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00754117 has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
Study Summary
Newly diagnosed DLCL patients will have baselne FDG-PET as part of initial staging (PET-1). Patients will then undergo 2 cycles of chemotherapy with R/CHOP. 14 to 21 days following cycle 2 of R/CHOP, patients will undergo repeat FDG-PET scan (PET-2). They will then complete therapy as planned. Following completion of therapy, standard response assessment will be performed, including CT scans of the chest, abdomen and pelvis and FDG-PET scan (PET-3).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-12-08 |
What the finished NCT00754117 record still lists
NCT00754117 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00754117 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00754117 about?
NCT00754117 is a clinical study titled "Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)". Newly diagnosed DLCL patients will have baselne FDG-PET as part of initial staging (PET-1). Patients will then undergo 2 cycles of chemotherapy with R/CHOP. 14 to 21 days following cycle 2 of R/CHOP, patients will undergo repeat FDG-PET scan (PET-2). They will then complete therapy as planned. Follo...
What is the current status of trial NCT00754117?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2008-05. Estimated completion is 2012-12-08.
Who is sponsoring clinical trial NCT00754117?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia